OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Medical Economics is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	141
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression	52
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	50
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction Act	48
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	45
Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): the influence of differing European health care payment systems on the potential fin	44
Economic value of intra-articular knee OA therapies: a U.S. perspective	43
Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective	31
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2– advanced breast cancer: a Medicare perspective	28
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	28
Calculating cost per event avoided using a composite number needed to treat	27
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment	26
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphom	26
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	25
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	24
The economic burden of systemic lupus erythematosus in Taiwan	24
Projected clinical and economic benefits of improved patent foramen ovale testing among cryptogenic stroke patients in the United States	24
Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia	23
Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening	23
Correction	23
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	22
Response to “methodological opacity in sword health digital pelvic health”	22